NervGen Pharma (STU:9UA) Valuation Rank

View and export this data going back to 2024. Start your Free Trial

What is NervGen Pharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

NervGen Pharma Valuation Rank Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

NervGen Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (STU:9UA) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

NGENF:USA NGEN:Canada

Address

112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4

Website

https://www.nervgen.com

NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.